Arteris, Inc. (NASDAQ:AIP – Get Free Report) major shareholder Bayview Legacy, Llc sold 100,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $23.82, for a total transaction of $2,382,000.00. Following the sale, the insider directly owned 8,129,071 shares in the company, valued at approximately $193,634,471.22. The trade was a 1.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Bayview Legacy, Llc also recently made the following trade(s):
- On Tuesday, September 1st, Bayview Legacy, Llc sold 100,000 shares of Arteris stock. The shares were sold at an average price of $20.75, for a total transaction of $2,075,000.00.
- On Tuesday, August 4th, Bayview Legacy, Llc sold 26,106 shares of Arteris stock. The shares were sold at an average price of $31.97, for a total transaction of $834,608.82.
- On Monday, August 3rd, Bayview Legacy, Llc sold 73,894 shares of Arteris stock. The stock was sold at an average price of $30.00, for a total transaction of $2,216,820.00.
Arteris Price Performance
Shares of AIP opened at $23.40 on Thursday. The firm has a market cap of $1.15 billion, a PE ratio of -26.90 and a beta of 1.90. The company has a current ratio of 1.57, a quick ratio of 1.57 and a debt-to-equity ratio of 0.03. The firm has a fifty day simple moving average of $24.57 and a two-hundred day simple moving average of $28.72. Arteris, Inc. has a 1-year low of $12.06 and a 1-year high of $50.26.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the stock. Roth Capital started coverage on shares of Arteris in a research note on Tuesday, August 4th. They issued a “buy” rating and a $40.00 price objective on the stock. Rosenblatt Securities restated a “buy” rating and set a $38.00 target price on shares of Arteris in a research report on Friday, August 7th. Weiss Ratings raised shares of Arteris from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. Jefferies Financial Group upgraded shares of Arteris from a “hold” rating to a “buy” rating and increased their price target for the stock from $35.00 to $50.00 in a research report on Friday, August 7th. Finally, Oppenheimer assumed coverage on shares of Arteris in a research note on Thursday, July 16th. They set an “outperform” rating and a $40.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Arteris presently has an average rating of “Moderate Buy” and a consensus price target of $39.43.
Get Our Latest Stock Report on AIP
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. WINTON GROUP Ltd bought a new position in shares of Arteris during the 2nd quarter valued at approximately $384,000. Spark Investment Management LLC bought a new stake in Arteris during the 2nd quarter worth approximately $1,074,000. Arizona State Retirement System bought a new stake in Arteris during the 2nd quarter worth approximately $442,000. Corient Private Wealth LP purchased a new position in Arteris during the second quarter valued at approximately $471,000. Finally, AXQ Capital LP purchased a new position in Arteris during the second quarter valued at approximately $661,000. 64.36% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting Arteris
Here are the key news stories impacting Arteris this week:
- Positive Sentiment: Arteris secured an additional $3.3 million through the Trusted and Assured Microelectronics program to expand its third-party semiconductor IP security-assurance initiative with BAE Systems and SiFive. The program could strengthen Arteris’ position in secure chip design, government projects and advanced semiconductor supply chains. Arteris funding announcement
- Positive Sentiment: Oppenheimer maintained its Buy rating on Arteris, providing continued support from Wall Street despite recent selling pressure. Oppenheimer rating report
- Neutral Sentiment: CEO K. Charles Janac, COO Laurent Moll and VP Paul Alpern reported multiple sales of vested shares. Several transactions were made to cover tax-withholding obligations, making them a weaker signal of declining management confidence; however, the repeated executive selling may still weigh on short-term sentiment. Arteris insider trading report
- Negative Sentiment: Bayview Legacy LLC sold 100,000 shares for roughly $2.38 million. Because the filing did not identify tax withholding as the reason, the sale may raise concerns about additional stock supply and investor conviction. Bayview Legacy share sale
- Negative Sentiment: Arteris’ latest reported quarter included an adjusted loss of $0.10 per share, worse than the expected $0.04 loss. Although revenue exceeded forecasts, the company remains loss-making, with analysts expecting a full-year loss.
About Arteris
Arteris, Inc is a semiconductor intellectual property (IP) company that develops technologies used in the design of system-on-chip (SoC) devices. Its products help semiconductor and electronics companies connect, manage and protect the various processing, memory and other functional components integrated into complex chips.
The company’s portfolio includes network-on-chip (NoC) interconnect IP, which supports communication among different elements within an SoC, as well as cache-coherent interconnect, system IP and related design technologies.
Further Reading
- Five stocks we like better than Arteris
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Arteris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arteris and related companies with MarketBeat.com's FREE daily email newsletter.
